BIIB

AI Research

Salanersen data presented → Motor milestones in SMA gene therapy patients

Biogen shares advanced 8.5% on February 6 following Q4 earnings that beat expectations with $2.3B revenue and $1.99 adjusted EPS versus $1.63 consensus. The company presented additional Salanersen data on March 11 showing new motor milestones in children with SMA previously treated with gene therapy, with Jefferies and Oppenheimer reaffirming Buy ratings. Year-to-date shares are up 8.6% with consensus Moderate Buy rating and $206.66 mean PT suggesting 8.6% upside.